THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, January 19, 2021
Accure Therapeutics, a European organization with an international focus, currently has three new chemical companies in its pipeline, possible disease-modifying drug candidates targeting core dysfunctions in CNS biology, with the potential to accommodate more.
FREMONT, CA: Accure Therapeutics, a private translational R&D engine at the clinical level in the Central Nervous System (CNS) area, recently announced the addition of five world-class neuroscience experts to its Scientific Advisory Board. They will continue to fuel creativity and campaign for Accure Therapeutics as the organization pushes its clinical trials' progress and the creation of novel therapies.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“We are proud and delighted with the appointment of our expert scientific advisory board members; each of whom is a highly experienced pioneer within his field of expertise. Their exceptional skills, talent and experience will help us to steer and refine the direction of our development. Their combined connections in academia and industry will help us establish instrumental partnerships,” said Pablo Villoslada, CSO, Accure Therapeutics.
Accure Therapeutics, a European organization with an international focus, currently has three new chemical companies in its pipeline, possible disease-modifying drug candidates targeting core dysfunctions in CNS biology, with the potential to accommodate more. It is one of the few EU firms with an agnostic approach to early research to produce novel drug-modifying diseases in the CNS. Recent appointments to the Science Advisory Board would enhance the company’s mission and strategic ambitions.
The appointees are:
• Prof. Stephen L. Hauser’s neurologist and former chair of neurology at UCSF (University of California, San Francisco), current director of the UCSF Weil Institute for Neuroscience. Pioneered genetics research in multiple sclerosis and anti-CD20 therapies
• Prof. Larry Steinman’s neurologist and former chair of the immunology program at Stanford University. Pioneer in new multiple sclerosis treatment (natalizumab), DNA vaccine. Part of the National Academy of Sciences and the National Academy of Medicine
• Prof. Amit Bar-Or Neurologist, Director of the Center for Neuroinflammation and Neurotherapeutics, Perelman School of Medicine, University of Pennsylvania. Pioneer in the roles of immune cell:brain-cell interactions and therapies in neuroimmunological disorders.
• Prof. Jose Obeso, Neurologist. Pioneer in clinical development of deep brain stimulation to treat Parkinson's disease and defined mechanisms associated with myoclonus, tics, and dystonia. Director of CINAC Neuroscience Center in Madrid, Professor of Neuroscience at CEU-San Pablo University.
“I am delighted to join Accure Therapeutics as a scientific advisory board member. The Accure team is fantastic, and the company is well-positioned to become a leader in CNS therapeutics. Disorders of the brain represent the next great area for growth in biotechnology. As scientific advisors, we will collectively address the largely unmet needs for disease modifying therapies and help position Accure for success in developing innovative drugs against serious brain disorders that affect more than one billion people worldwide,” said Prof. Stephen L. Hauser.
More in News